Evidence map›Paper›PMID 36826116›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients.

Paul Zarogoulidis, Dimitrios Petridis, Christoforos Kosmidis, Konstantinos Sapalidis, Lila Nena, Dimitrios Matthaios, Konstantinos Porpodis, Paschalis Kakavelas, Paschalis Steiropoulos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Paul ZarogoulidisPulmonary Department, General Clinic Euromedica Private Hospital, 851 05 Thessaloniki, Greece.ORCID 0000-0001-5119-2207
Dimitrios PetridisDepartment of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, 574 00 Thessaloniki, Greece.
Christoforos Kosmidis3rd Surgery Department, AHEPA University Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Konstantinos Sapalidis3rd Surgery Department, AHEPA University Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Lila NenaLaboratory of Social Medicine, Medical School, Democritus University of Thrace, 691 00 Alexandroupolis, Greece.
Dimitrios MatthaiosOncology Department, General Hospital of Rhodes, 851 00 Rhodes, Greece.
Konstantinos PorpodisPulmoanry Department, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0001-7215-2191
Paschalis KakavelasIntensive Care Unit (ICU), General Clinic Euromedica, 153 43 Thessaloniki, Greece.
Paschalis SteiropoulosDepartment of Respiratory Medicine, Medical School, Democritus University of Thrace, 691 00 Alexandroupolis, Greece.
Aristotle University of Thessaloniki · GRDemocritus University of Thrace · GRAlexander Technological Educational Institute of Thessaloniki · GREuromedica · GRGeneral Hospital of Rhodes · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCancer patients are known to experience sleep disturbances that differ between disease stages and treatments. Regarding lung cancer patients and immunotherapy, information on their sleep disturbances has been recently acquired, but no comparison has been made between different treatment modalities. PATIENTS AND

methodsWe recruited 98 non-small cell lung cancer patients; 49 had programmed death-ligand 1 expression of ≥50% and received immunotherapy as first-line treatment and 49 had programmed death-ligand 1 expression in the range from 0-49 and received chemotherapy as first-line treatment. All patients were stage IV, but with no bone metastasis. Sleep disturbances were recorded through polysomnography and sleep questionnaires.

resultsFor immunotherapy patients with PD-L1 expression ≥ 50%, the disease response was rapid and the sleep disturbances decreased rapidly. On the other hand, for chemotherapy patients, the sleep disturbances remained for all those patients that had partial response and stable disease. It was noticed that chemotherapy drugs induce severe adverse effects. DISCUSSION: In our study, it was observed that patients with complete response had reduced sleep disturbances in the case of immunotherapy patients. However, sleep disturbances continued for several patients in the chemotherapy group due to the adverse effects of chemotherapy drugs. IN

conclusionImmunotherapy drugs on their own do not induce sleep disturbances and, through treatment response, alleviate sleep disturbances in lung cancer patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunotherapycancerchemotherapyfatigueinsomnialung cancerpolysomnographysleep disturbances

Identifiers

PMID36826116
PMCPMC9955782
OpenAlexW4319297059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.